Predicting the outcome of prostate biopsy: comparison of a novel logistic regression‐based model, the prostate cancer risk calculator, and prostate‐specific antigen level alone

To develop a logistic regression‐based model to predict prostate cancer biopsy at, and compare its performance to the risk calculator developed by the Prostate Cancer Prevention Trial (PCPT), which was based on age, race, prostate‐specific antigen (PSA) level, a digital rectal examination (DRE), family history, and history of a previous negative biopsy, and to PSA level alone.

[1]  A. Partin,et al.  An algorithm combining age, total prostate-specific antigen (PSA), and percent free PSA to predict prostate cancer: results on 4298 cases. , 1998, Urology.

[2]  G Bartsch,et al.  Age, prostate-specific antigen, and digital rectal examination as determinants of the probability of having prostate cancer. , 2001, Urology.

[3]  H. Carter,et al.  PSA velocity for the diagnosis of early prostate cancer. A new concept. , 1993, The Urologic clinics of North America.

[4]  M. Kattan,et al.  Development of a nomogram that predicts the probability of a positive prostate biopsy in men with an abnormal digital rectal examination and a prostate-specific antigen between 0 and 4 ng/mL. , 1999, Urology.

[5]  Mesut Remzi,et al.  Novel artificial neural network for early detection of prostate cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  David Aaron,et al.  A New Concept , 1974 .

[7]  Klaus Jung,et al.  Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate‐specific antigen levels ≤ 10 ng/ml , 2004, Cancer.

[8]  Michael M Lieber,et al.  Journal Review , 2003, International Society of Hair Restoration Surgery.

[9]  Klaus Jung,et al.  Multicenter evaluation of an artificial neural network to increase the prostate cancer detection rate and reduce unnecessary biopsies. , 2002, Clinical chemistry.

[10]  I. Thompson,et al.  Prostate rebiopsy is a poor surrogate of treatment efficacy in localized prostate cancer. , 1998, The Journal of urology.

[11]  A. Haese*,et al.  Development and external validation of an extended 10-core biopsy nomogram. , 2007, European urology.

[12]  T. Stamey,et al.  Multicenter comparison of the diagnostic performance of free prostate-specific antigen. , 1996, Urology.

[13]  M. Kattan,et al.  Prostate cancer nomograms: an update. , 2006, European urology.

[14]  Ziding Feng,et al.  Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. , 2006, Journal of the National Cancer Institute.

[15]  I. Thompson,et al.  Development of a decision-making tool to predict risk of prostate cancer: the Cancer of the Prostate Risk Index (CAPRI) test. , 1997, Urology.

[16]  Walter J. Simoneaux,et al.  African‐American race is a predictor of prostate cancer detection: incorporation into a pre‐biopsy nomogram , 2006, BJU international.

[17]  M. Kattan,et al.  A nomogram for predicting a positive repeat prostate biopsy in patients with a previous negative biopsy session. , 2009, The Journal of urology.

[18]  Javier Hernandez,et al.  External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population. , 2006, Urology.

[19]  Ian M Thompson,et al.  Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. , 2005, JAMA.

[20]  W. Fair,et al.  Incidence and clinical significance of false-negative sextant prostate biopsies. , 1998, The Journal of urology.

[21]  Yi-Ching Hsieh,et al.  Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate specific antigen levels ≤ 10 ng/mL , 2003, Cancer.

[22]  G. Pond,et al.  Nomogram prediction for prostate cancer and aggressive prostate cancer at time of biopsy: utilizing all risk factors and tumor markers for prostate cancer. , 2006, The Canadian journal of urology.

[23]  Pierre I Karakiewicz,et al.  Initial biopsy outcome prediction--head-to-head comparison of a logistic regression-based nomogram versus artificial neural network. , 2007, European urology.

[24]  Carter Hb,et al.  PSA velocity for the diagnosis of early prostate cancer. A new concept. , 1993 .

[25]  T. Wheeler,et al.  Predictors of prostate cancer after initial negative systematic 12 core biopsy. , 2004, The Journal of urology.

[26]  M. Kattan,et al.  Comparisons of nomograms and urologists' predictions in prostate cancer. , 2002, Seminars in urologic oncology.

[27]  M. Kattan,et al.  Development and validation of a nomogram predicting the outcome of prostate biopsy based on patient age, digital rectal examination and serum prostate specific antigen. , 2005, The Journal of urology.

[28]  A. Haese*,et al.  Development and external validation of an extended repeat biopsy nomogram. , 2007, The Journal of urology.

[29]  M. Kattan,et al.  Validation of a nomogram for predicting positive repeat biopsy for prostate cancer. , 2005, The Journal of urology.

[30]  T. Stamey,et al.  Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial. , 2003, The Journal of urology.

[31]  Tomohiko Ichikawa,et al.  Development of a nomogram to predict probability of positive initial prostate biopsy among Japanese patients. , 2006, Urology.

[32]  P. Carroll,et al.  Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower , 2005 .